论文部分内容阅读
Purpose: To evaluate observed and relative survival rates, enucleation rates, and visual outcome after ruthenium 106 brachytherapy for uveal melanoma. Design: Retrospective cases series from the Swedish national referral center. Participants: Five hundred seventy-nine patients (579 eyes) with choroidal or ciliary body melanomas, including 55 tumors more than 7 mm in height, treated with ruthenium episcleral plaques from January, 1979, through April, 2003. Methods: Clinical and radiotherapy data were extracted from a dedicated database, and survival status was determined through population registries. Tumor size was classified according to the Collaborative Ocular Melanoma Study criteria. The 5-and 10-year relative survival rates were estimated, and univariate and multivariate regression models were constructed for predictive factors on observed survival, enucleation, and visual deterioration. Main Outcome Measures: Observed and relative survival rate, proportion of secondary enucleation, deterioration of visual acuity to less than 0.5, respectively, to 0.1 or worse. Results: Tumors were classified as small in 10.5%, medium in 78.4%, and large in 9.2%of patients. The 5-and 10-year observed overall survival rates were 83.3%and 71.5%, respectively, and the corresponding relative rates were 95.5%and 94%, respectively. Factors predicting survival were tumor diameter, patient age, and secondary enucleation. One hundred six patients (18%) underwent enucleation up to 14 years after plaque treatment. The only predictive factor for enucleation was tumor size. At 5 years, 31%of the patients retained 0.5 visual acuity or better, and 49%retained better than 0.1 visual acuity. Predictive factors for visual deterioration were visual acuity and distance from posterior tumor border to the foveola. Conclusions: After ruthenium brachytherapy for uveal melanoma, the survival rates and visual outcomes in this populationbased investigationwere similar to previously published results. The eye was retained in 81.7%of patients. Careful patient selection (presently we only treat melanomas 7 mm or smaller in height) and life-long monitoring for recurrences is warranted.
Purpose: To evaluate observed and relative survival rates, enucleation rates, and visual outcome after ruthenium 106 brachytherapy for uveal melanoma. Design: Retrospective cases series from the Swedish national referral center. Participants: Five hundred seventy-nine patients (579 eyes) with choroidal or ciliary body melanomas, including 55 tumors more than 7 mm in height, treated with ruthenium episcleral plaques from January, 1979, through April, 2003. Methods: Clinical and radiotherapy data were extracted from a dedicated database, and survival status was determined through population The 5-and 10-year relative survival rates were estimated, and univariate and multivariate regression models were constructed for predictive factors on observed survival, enucleation, and visual deterioration. Main Outcome Measures: Observed and relative survival rate, proportion of secondary enucleatio Results: Tumors were classified as small in 10.5%, medium in 78.4%, and large in 9.2% of patients. The 5-and 10-year observed Overall predictive survival was 95.5% and 94%, respectively, and the corresponding relative rates were 95.5% and 94%, respectively. Factors predicting survival of tumor diameter, patient age, and secondary enucleation. One hundred six patients (18%) underwent enucleation The only predictive factor for enucleation was tumor size. At 5 years, 31% of the patients retained 0.5 visual acuity or better, and 49% retained better than 0.1 visual acuity. Predictive factors for visual deterioration were visual acuity and distance from posterior tumor border to the foveola. Conclusions: After ruthenium brachytherapy for uveal melanoma, the survival rates and visual outcomes in this population based investigationwere similar to previously published results. Theeye was retained in 81.7% of patients. Careful patient selection (presently we only treat melanomas 7 mm or smaller in height) and life-long monitoring for recurrences is warranted.